ArticleHepatology communications2022
A higher FIB-4 index is associated with an increased incidence of renal failure in the general population.
Article in Hepatology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye.Hepatology international · 2026Article
- Noninvasive Tests for Liver Fibrosis Predict Postoperative Complications After Resection of Colorectal Liver Metastases.Annals of surgical oncology · 2026Article
- Prognostic value of the fibrosis-4 index for predicting in-hospital mortality in sepsis patients: evidence from MIMIC-IV and eICU databases.Scientific reports · 2026Article
- Unveiling the prognostic power of FIB-4 index: a new frontier in heart failure mortality.European journal of medical research · 2025Article
- Integrative Assessment of TyG Index, FIB-4, and eGFR as Composite Predictors of Metabolic Risk Clusters in Adults.Metabolites · 2025Article
- SGLT2 Inhibitors Modify Fibrosis-4 Index and Mitigate the Development of DKD: Role of Background Antidiabetic Drugs.Journal of the Endocrine Society · 2025Article
- Inflammatory and fibrosis indices (UA/Alb, Fib/UA, UA/Cr, Cr/BW, AST/PLT, AST/ALT, FIB-4, and FIB-5) as predictors of preeclampsia-associated systemic dysfunction.BMC pregnancy and childbirth · 2025Article
- Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease.BMC endocrine disorders · 2025Article
- Fibrosis-4 index is closely associated with future development of hypertension in the Japanese general population.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Article
- Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis.Global health & medicine · 2024Article
- Association Between Noninvasive Liver Fibrosis Scores and Heart Failure in a General Population.Journal of the American Heart Association · 2024Article
- The Roles of Liver Fibrosis Scores and Modified Stress Hyperglycemia Ratio Values in Predicting Contrast-Induced Nephropathy after Elective Endovascular Infrarenal Abdominal Aortic Aneurysm Repair.Healthcare (Basel, Switzerland) · 2023Article
- A higher FIB-4 index is associated with an increased incidence of renal failure in the general population.Hepatology communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Fibrosis-4 index (FIB-4) is a recommended noninvasive fibrosis test in patients at risk of liver fibrosis. Chronic liver diseases are often associated with kidney diseases. This study aimed to investigate the association between FIB-4 and the development of renal failure among the general population. For this study, we used the Disease Analyzer database, which includes diagnoses and basic medical and demographic data of patients followed in general practices in Germany. Using these data, we extensively matched patients with a FIB-4 index ≥ 1.3 (n = 66,084) to patients with a FIB-4 index < 1.3 (n = 66,084). The primary outcome was the incidence of renal failure or chronic renal failure during a 10-year period. Within 10 years of the index date, 9.2% of patients with a FIB-4 < 1.3 and 10.6% of patients with a FIB-4 ≥ 1.3 were diagnosed with renal failure (p = 0.007). The endpoint chronic renal failure was reached by 7.9% with a FIB-4 < 1.3 and 9.5% with a FIB-4 ≥ 1.3 (p < 0.001). A FIB-4 index ≥ 1.3 was associated with a slight increase in renal failure incidence (hazard ratio [HR]: 1.08, p = 0.009). There was an increasing association between an increase in FIB-4 index and the incidence of renal failure with the strongest association for a FIB-4 index ≥ 2.67 (HR: 1.34, p = 0.001). In sensitivity analyses, a significant association was found for the age group of 51-60 years (HR: 1.38, p < 0.001), patients with arterial hypertension (HR: 1.15, p < 0.001), obese patients (HR: 1.25, p = 0.005), and patients with lipid metabolism disorders (HR:1.22, p < 0.001). Conclusion: A higher FIB-4 index is associated with an increased incidence of renal failure. Therefore, the FIB-4 index may be useful in identifying patients who are at risk not only for liver-related events but also for renal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.